BioSpace News Archive

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its development partner, Kaken Pharmaceutical Co. Ltd. (“Kaken”) submitted a new drug application for approval of manufacturing and marketing for sofpironium bromide in Japan for primary axillary hyperhidrosis.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a strategic outlook for 2020 outlining key priorities for its broad pipeline.

The Finnish medical technology company Planmed Oy and the UK-based medical X-ray software solutions provider IBEX Innovations Ltd. have signed a collaboration agreement

Companion Medical, Inc. announced that it has entered into a loan and security agreement for up to $27.5 million with K2 HealthVentures, a healthcare-focused specialty finance company.

Paradigm Diagnostics, Inc. announced that Palmetto GBA, the Medicare Administrative Contractor for the Molecular Diagnostics MolDX program, has reviewed the technical dossier and broadly approved the Paradigm Cancer Diagnostic assay under the Local Coverage Determination for next-generation sequencing for solid tumors..

ALPHAEON Corporation, announced that it has completed a reorganization to simplify its corporate structure. As a result of this reorganization the company has split into two business units, each of which will retain the same shareholder base that was in place prior to this split off..

Shares of the Combined Company, NeuroBo Pharmaceuticals, Began Trading on the Nasdaq Exchange Under the Symbol NRBO on December 31, 2019

Kronos Bio, Inc. announced that Norbert Bischofberger, Ph.D., President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 10:30 a.m. Pacific Time.

InMed Pharmaceuticals Inc. confirmed that at its annual general meeting of shareholders held on December 19, 2019, all directors nominated as listed in the information circular dated November 7, 2019 were elected as directors of the Company for the ensuing year.